2021
Overcoming Barriers to Radiation Oncology Access in Low-Resource Settings in the United States
Mattes MD, Suneja G, Haffty BG, Takita C, Katz MS, Ohri N, Deville C, Siker ML, Park HS. Overcoming Barriers to Radiation Oncology Access in Low-Resource Settings in the United States. Advances In Radiation Oncology 2021, 6: 100802. PMID: 34693080, PMCID: PMC8515237, DOI: 10.1016/j.adro.2021.100802.Peer-Reviewed Original ResearchPatient populationVulnerable patient populationEquitable cancer careAmerican SocietyQuality Improvement ProgramRadiation Oncology CommitteeHypofractionation schedulesCancer careOncology CommitteeRadiation therapyRadiation oncologistsEducational sessionsResource settingsHealth equityCommunity practiceHospital leadership
2018
Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing
Kim AS, Bartley AN, Bridge JA, Kamel-Reid S, Lazar AJ, Lindeman NI, Long TA, Merker JD, J. AJ, Rimm DL, Rothberg PG, Vasalos P, Moncur JT. Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing. JAMA Oncology 2018, 4: 838-841. PMID: 29242895, PMCID: PMC6145687, DOI: 10.1001/jamaoncol.2017.4021.Peer-Reviewed Original ResearchConceptsLaboratory-developed testsPT responseCompanion diagnosticsClinical laboratory testingKRAS testingOncology CommitteeMAIN OUTCOMEUS FoodDrug AdministrationPractice characteristicsDiagnostic testingTumor contentProficiency testingVariant-specific differencesEGFRBRAFClinical diagnostic testingMajority of laboratoriesKRASAssaysLaboratory testingPerformance of laboratoriesKit manufacturersResponseParticipants
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply